| Date:                         | 12/20/2023  |
|-------------------------------|---|
| Your Name:                    | Taesik Gwag   |
| Manuscript Title:             | Platelet-derived thrombospondin1 promotes immune cell liver infilatration |
| Manuscript Number (if known): | JHEPR-D-23-01017  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you hav relationship or indicate none (add row |   | were |
|---|---|--|---|------|
|   |   | Time frame: Since the  | initial planning of the work              |      |
| 1 | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br><b>No time limit for<br/>this item.</b> | None   | Click the tab key to add additional rows. |      |
|   |   | Time frame:  | : past 36 months                          |      |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | ⊠         None   |   |      |
| 3 | Royalties or<br>licenses  | None   |   |      |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | ☑         None   |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | ☑         None   |   |
| 6  | Payment for<br>expert testimony   | ⊠         None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | ⊠         None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | ⊠       None         □       □         □       □         □       □                           |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | ⊠         None   |   |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | ⊠         None   |   |

|      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|---|---|
| 11   | Stock or stock<br>options   | ⊠       None  |   |
| 12   | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services | <ul> <li>□</li> <li>□</li></ul> |   |
| 13   | Other financial or<br>non-financial<br>interests  | None  |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:                 |   |   |

| Date:                         | 12/20/2023  |
|-------------------------------|---|
| Your Name:                    | Sangderk Lee  |
| Manuscript Title:             | Platelet-derived thrombospondin1 promotes immune cell liver infilatration |
| Manuscript Number (if known): | JHEPR-D-231017  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed | Specifications/Comments (e.g., if payments were<br>made to you or to your institution) |
|---|---|---|--|
|   |   | Time frame: Since the initial planni  | ng of the work   |
| 1 | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br>No time limit for<br>this item. | None  | Click the tab key to add additional rows.  |
|   |   | Time frame: past 36 mor   | ths  |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | ⊠         None  |  |
| 3 | Royalties or<br>licenses  | ⊠ None  |  |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | ☑         None   |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | ☑         None   |   |
| 6  | Payment for<br>expert testimony   | ⊠         None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | ⊠         None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | ⊠         None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | ⊠         None   |   |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | ⊠       None         □       □         □       □         □       □                           |   |

|      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|---|---|
| 11   | Stock or stock<br>options   | ⊠       None  |   |
| 12   | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services | <ul> <li>□</li> <li>□</li></ul> |   |
| 13   | Other financial or<br>non-financial<br>interests  | None  |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:                 |   |   |

| Date:                         | 12/20/2023  |
|-------------------------------|---|
| Your Name:                    | Zhenyu Li   |
| Manuscript Title:             | Platelet-derived thrombospondin1 promotes immune cell liver infilatration |
| Manuscript Number (if known): | Click or tap here to enter text.  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | e all entities with whom you have this<br>onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
|   | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br>No time limit for<br>this item. | None   | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 month  | S   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None   |   |
| 3 | Royalties or<br>licenses  | None   |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | ☑         None   |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | ☑         None   |   |
| 6  | Payment for<br>expert testimony   | ⊠         None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | ⊠         None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | ⊠         None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | ⊠         None   |   |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | ⊠       None         □       □         □       □         □       □                           |   |

|      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|---|---|
| 11   | Stock or stock<br>options   | ⊠       None  |   |
| 12   | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services | <ul> <li>□</li> <li>□</li></ul> |   |
| 13   | Other financial or<br>non-financial<br>interests  | None  |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:                 |   |   |

| Date:                         | 12/20/2023  |
|-------------------------------|---|
| Your Name:                    | Alana Newcomb   |
| Manuscript Title:             | Platelet-derived thrombospondin1 promotes immune cell liver infilatration |
| Manuscript Number (if known): | JHEPR-D-23-01017  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | e all entities with whom you have this<br>onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
|   | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br>No time limit for<br>this item. | None   | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 month  | S   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None   |   |
| 3 | Royalties or<br>licenses  | None   |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | ☑         None   |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | ☑         None   |   |
| 6  | Payment for<br>expert testimony   | ⊠         None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | ⊠         None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | ⊠       None         □       □         □       □         □       □                           |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | ⊠         None   |   |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | ⊠         None   |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|---|---|
| 11 | Stock or stock<br>options   | ⊠       None  |   |
| 12 | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services | <ul> <li>□</li> <li>□</li></ul> |   |
| 13 | Other financial or<br>non-financial<br>interests  | None  |   |
|    | Please place an "X" next to the following statement to indicate your agreement:                 |   |   |

| Date:                         | 12/20/2023  |
|-------------------------------|---|
| Your Name:                    | Josephine Otuagomah   |
| Manuscript Title:             | Platelet-derived thrombospondin1 promotes immune cell liver infilatration |
| Manuscript Number (if known): | JHEPR-D-23-01017  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning of the work   |   |
|   | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br>No time limit for<br>this item. | ☑       None         ☑   | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 month  | IS  |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None   |   |
| 3 | Royalties or<br>licenses  | None   |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | ☑         None   |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | ☑         None   |   |
| 6  | Payment for<br>expert testimony   | ⊠         None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | ⊠         None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | ⊠         None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | ⊠         None   |   |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | ⊠       None         □       □         □       □         □       □                           |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|---|---|
| 11 | Stock or stock<br>options   | ⊠       None  |   |
| 12 | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services | <ul> <li>□</li> <li>□</li></ul> |   |
| 13 | Other financial or<br>non-financial<br>interests  | None  |   |
|    | Please place an "X" next to the following statement to indicate your agreement:                 |   |   |

| Date:                         | 12/20/2023  |
|-------------------------------|---|
| Your Name:                    | Steven Weinman  |
| Manuscript Title:             | Platelet-derived thrombospondin1 promotes immune cell liver infilatration |
| Manuscript Number (if known): | JHEPR-D-23-01017  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)   | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning o   | of the work   |
| 1 | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br>No time limit for<br>this item. | None         National Institutes of Health (NIH) Grant<br>(DK131786)         Image: | Click the tab key to add additional rows.   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | ⊠         None   |   |
| 3 | Royalties or<br>licenses  | None   |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | ☑         None   |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | ☑         None   |   |
| 6  | Payment for<br>expert testimony   | ⊠         None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | ⊠         None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | ⊠         None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | ⊠         None   |   |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | ⊠       None         □       □         □       □         □       □                           |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|---|---|
| 11 | Stock or stock<br>options   | ⊠       None  |   |
| 12 | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services | <ul> <li>□</li> <li>□</li></ul> |   |
| 13 | Other financial or<br>non-financial<br>interests  | None  |   |
|    | Please place an "X" next to the following statement to indicate your agreement:                 |   |   |

| Date:                         | 12/20/2023  |
|-------------------------------|---|
| Your Name:                    | Ying Liang  |
| Manuscript Title:             | Platelet-derived thrombospondin1 promotes immune cell liver infilatration |
| Manuscript Number (if known): | JHEPR-D-23-01017  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | e all entities with whom you have this<br>onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
|   | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br>No time limit for<br>this item. | None   | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 month  | S   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None   |   |
| 3 | Royalties or<br>licenses  | None   |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | ☑         None   |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | ☑         None   |   |
| 6  | Payment for<br>expert testimony   | ⊠         None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | ⊠         None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | ⊠         None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | ⊠         None   |   |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | ⊠       None         □       □         □       □         □       □                           |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|---|---|
| 11 | Stock or stock<br>options   | ⊠       None  |   |
| 12 | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services | <ul> <li>□</li> <li>□</li></ul> |   |
| 13 | Other financial or<br>non-financial<br>interests  | None  |   |
|    | Please place an "X" next to the following statement to indicate your agreement:                 |   |   |

| Date:                         | 12/20/2023  |
|-------------------------------|---|
| Your Name:                    | Changcheng Zhou   |
| Manuscript Title:             | Platelet-derived thrombospondin1 promotes immune cell liver infilatration |
| Manuscript Number (if known): | JHEPR-D-23-01017  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | e all entities with whom you have this<br>onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
|   | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br>No time limit for<br>this item. | None   | Click the tab key to add additional rows.   |
|   |   | Time frame: past 36 month  | S   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | None   |   |
| 3 | Royalties or<br>licenses  | None   |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | ☑         None   |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | ☑         None   |   |
| 6  | Payment for<br>expert testimony   | ⊠         None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | ⊠         None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | ⊠       None         □       □         □       □         □       □                           |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | ⊠         None   |   |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | ⊠         None   |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)  | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|---|---|
| 11 | Stock or stock<br>options   | ⊠       None  |   |
| 12 | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services | <ul> <li>□</li> <li>□</li></ul> |   |
| 13 | Other financial or<br>non-financial<br>interests  | None  |   |
|    | Please place an "X" next to the following statement to indicate your agreement:                 |   |   |

| Date:                         | 12/20/2023  |
|-------------------------------|---|
| Your Name:                    | Shuxia Wang   |
| Manuscript Title:             | Platelet-derived thrombospondin1 promotes immune cell liver infiltration and exacerbates diet-induced steatohepatitis |
| Manuscript Number (if known): | JHEPR-D-23-01017  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed)   | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial planning   | of the work   |
| 1 | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br><b>No time limit for<br/>this item.</b> | <ul> <li>None</li> <li>National Institutes of Health (NIH) Grant<br/>(DK131786)</li> <li>Department of Veterans Affairs Merit Review<br/>Award (BX004252)</li> <li>Institutional Development Award (IDeA) from the<br/>National Institute of General Medical Sciences of<br/>the National Institutes of Health under grant<br/>number P30 GM127211.</li> </ul>   | Click the tab key to add additional rows.   |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | Time frame: past 36 month          Image: Display the second sec | S   |
| 3 | Royalties or<br>licenses  | None   |   |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | ☑         None           □         □           □         □           □         □             |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None   |   |
| 6  | Payment for<br>expert testimony   | None   |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | ⊠         None   |   |
| 8  | Patents planned,<br>issued or<br>pending  | None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | ⊠  None<br>  |   |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | ⊠         None   |   |

|      |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|---|--|---|
| 11   | Stock or stock<br>options   | ⊠       None   |   |
| 12   | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services | ⊠       None   |   |
| 13   | Other financial or<br>non-financial<br>interests  | None   |   |
| Plea | Please place an "X" next to the following statement to indicate your agreement:                 |  |   |